A single-arm, open-label phase II clinical trial of SHR-1210 (camrelizumab) in combination with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma.

被引：0
|
作者：
Wang, Feng
Xia, Jin
Meng, Xiangrui
Ji, Yinghua
Yang, Xiuli
Hong, Yong-Gui
Wang, Junsheng
Cui, Donghai
Luo, Zhiquan
机构：
[1] Zhengzhou Univ, Affiliated Canc Hosp 1, Henan Canc Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
[2] Anyang Tumor Hosp, Anyang, Henan, Peoples R China
[3] Zhengzhou Univ, Affiliated Hosp 1, Dept Med Oncol, Zhengzhou, Peoples R China
[4] Xinxiang Med Univ, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China
[5] Nanyang Med Coll, Affiliated Hosp 1, Nanyang, Peoples R China
[6] Anyang Tumor Hosp, Dept Oncol, Anyang, Henan, Peoples R China
[7] Xinyang Tumor Hosp, Xinyang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16007
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial
    Guozhen Yang
    Xiaodong Su
    Yuanheng Huang
    Guangyu Luo
    Zhiqiang Wang
    Peiqiang Cai
    Yating Zheng
    Ting Bei
    Mengli Huang
    Yuezong Bai
    Haoqiang He
    Jin Xiang
    Muyan Cai
    Jiudi Zhong
    Qiyu Guo
    Xu Zhang
    Journal of Translational Medicine, 21
  • [32] Update results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Chang, Zhiwei
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Wang, Rui-Rui
    Jia, Yong-Xu
    Yan, Jie
    Qin, Yanru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Zhang, Yan-Feng
    Hao, An-Lin
    Hong, Yong-Gui
    Li, Xiao-Ming
    Liang, Wei-Min
    Zheng, Zhi-Xin
    Yang, Guang-Yi
    Guo, Xiao-Feng
    Wen, Yan-Yan
    Cao, Heng
    Le, Cheng
    Song, Hua-Jie
    Su, Wen-Zhong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16015 - E16015
  • [34] Neoadjuvant camrelizumab combined with chemotherapy and apatinib for locally advanced thoracic esophageal squamous cell carcinoma (ESCC): A single-arm, open-label, phase Ib study.
    Wang, Zhen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial
    Zhang, Changgong
    Chen, Jianhua
    Wu, Huijuan
    Wang, Jun
    Gao, Liying
    Zhao, Jun
    Sun, Yan
    Jia, Zhongyao
    Mu, Xinlin
    Bai, Chunmei
    Wang, Rui
    Wu, Kailiang
    Liu, Qiang
    Shi, Yuankai
    CANCER PATHOGENESIS AND THERAPY, 2024, 2 (04): : 268 - 275
  • [36] Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial
    Jin, Shuiling
    Zhao, Ruihua
    Zhou, Chuang
    Zhong, Qian
    Shi, Jianxiang
    Su, Chang
    Li, Qinglong
    Su, Xiaoxing
    Chi, Huabin
    Lu, Xu
    Jiang, Guozhong
    Chen, Renyin
    Han, Jinming
    Jiang, Miao
    Qiao, Shishi
    Liu, Jingjing
    Song, Min
    Song, Lijie
    Du, Yabing
    Chang, Zhiwei
    Wang, Meng
    Dong, Meilian
    Zhong, Yali
    Yu, Pu
    Zhang, Xiaojian
    Zong, Hong
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (08) : 1648 - 1658
  • [37] Preoperative camrelizumab combined with chemotherapy for borderline resectable esophageal squamous cell carcinoma (BRES-1): A single-arm, open-label, phase II study.
    Yang, Hang
    Zhang, Guoqing
    Li, Xiangnan
    Jiao, Jia
    Guo, Yanan
    Zhang, Yan
    Hou, Zhichao
    Huang, Qi
    Zhao, Jia
    Li, Jindong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 360 - 360
  • [38] Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: An open-label single-arm study
    Chang, Gee-Chen
    Tsai, Chun-Ming
    Hsia, Te-Chun
    Yang, Chih-Hsin
    Abdulnabi, Radhi
    Blair, Julie M.
    Linn, Carlos
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2013, 112 (09) : 518 - 526
  • [39] Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
    Trigo, Jose
    Subbiah, Vivek
    Besse, Benjamin
    Moreno, Victor
    Lopez, Rafael
    Sala, Maria Angeles
    Peters, Solange
    Ponce, Santiago
    Fernandez, Cristian
    Alfaro, Vicente
    Gomez, Javier
    Kahatt, Carmen
    Zeaiter, Ali
    Zaman, Khalil
    Boni, Valentina
    Arrondeau, Jennifer
    Martinez, Maite
    Delord, Jean-Pierre
    Awada, Ahmad
    Kristeleit, Rebecca
    Olmedo, Maria Eugenia
    Wannesson, Luciano
    Valdivia, Javier
    Rubio, Maria Jesus
    Anton, Antonio
    Sarantopoulos, John
    Chawla, Sant P.
    Mosquera-Martinez, Joaquin
    D'Arcangelo, Manolo
    Santoro, Armando
    Villalobos, Victor M.
    Sands, Jacob
    Paz-Ares, Luis
    LANCET ONCOLOGY, 2020, 21 (05): : 645 - 654
  • [40] Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research
    Wang, X.
    Ma, J.
    Zhang, J.
    Yang, Y.
    Zheng, D.
    Liang, H.
    Zhang, L.
    Xin, Y.
    Ling, X.
    Fang, C.
    Jiang, H.
    Zheng, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S1400 - S1400
12345